Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

Annals of Neurology

Volumn 59, Issue 3, 2006, Pages 490-498

  Franz, David Neal ^a,c   Leonard, Jennifer ^a   Tudor, Cynthia ^a   Chuck, Gail ^a   Care, Marguerite ^a   Sethuraman, Gopalan ^b   Dinopoulos, Argirios ^a   Thomas, George ^a   Crone, Kerry R ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPID; PHENOBARBITAL; RAPAMYCIN; TOPIRAMATE; VALPROATE SEMISODIUM; VIGABATRIN;

ACNE; ADOLESCENT; ADULT; APHTHOUS ULCER; ARTICLE; ASTROCYTOMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; FEMALE; GENETIC DISORDER; HUMAN; HUMAN TISSUE; HYDROCEPHALUS; IMAGING SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; LIPID BLOOD LEVEL; MALE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; SIDE EFFECT; TUBEROUS SCLEROSIS; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION;

ADOLESCENT; ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MODELS, BIOLOGICAL; REGRESSION (PSYCHOLOGY); SIROLIMUS; TUBEROUS SCLEROSIS;

EID: 33644827461     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20784     Document Type: Article

References (32)

1. Torres OA, Roach ES, Delgado MR, et al. Early diagnosis of subependymal giant cell astrocytoma in patients with tuberous sclerosis. J Child Neurol 1998;13:173-177.
2. Sinson G, Sutton LN, Yachnis AT, et al. Subependymal giant cell astrocytomas in children. Pediatr Neurosurg 1994;20:233-239.
3. Cuccia V, Zuccaro G, Sosa F, et al. Subependymal giant cell astrocytoma in children with tuberous sclerosis. Childs Nerv Syst 2003;19:232-243.
4. Shields JA, Eagle RC Jr, Shields CL, et al. Aggressive retinal astrocytomas in four patients with tuberous sclerosis complex. Trans Am Ophthalmol Soc 2004;102:139-148.
5. Dashti SR, Robinson S, Rodgers M, et al. Pineal region giant cell astrocytoma associated with tuberous sclerosis: case report. J Neurosurg 2005;102(3 suppl):322-325.
6. Medhkour A, Traul D, Husain M. Neonatal subependymal giant cell astrocytoma. Pediatr Neurosurg 2002;36:271-274.
7. Matsumura H, Takimoto H, Shimada N, et al. Glioblastoma following radiotherapy in a patient with tuberous sclerosis. Neurol Med Chir (Tokyo) 1998;38:287-291.
8. Kwiatkowski DJ. Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther 2003;2:471-476.
9. Nobukini T, Thomas G. The mTOR/S6K signaling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb. Novartis Found Symp 2004;262:148-159, 265-268.
10. Dasgupta B, Yi Y, Chen D, et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005;65:2755-2760.
11. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCi-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005;65:2825-2831.
12. Rizell M, Lindner P. Inhibition of mTOR suppresses experimental liver tumours. Anticancer Res 2005;25(2A):789-793.
13. Ma L, Chen Z, Erdjument-Bromage H, et al. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005;121:179-193.
14. Asano T, Yao Y, Zhu J, et al. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005;331:295-302.
15. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 2005;25:212-225.
16. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005;11:353-361.
17. Jiang WG, Sampson J, Martin TA, et al. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes. Eur J Cancer 2005;41:1628-l636.
18. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005;11:5319-5328.
19. Chapman T, Perry C. Everolimus. Drugs 2004;64:861-872.
20. Temsirolimus: CCI 779, CCI-779, cell cycle inhibitor-779. Drugs RD 2004;5:363-367.
21. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol 2005;56:47-60.
22. Kenerson H, Dundon TA, Yeung RS. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 2005;57:67-75.
23. Cuba M, Yezhelvev M, Eichhorn ME, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the present of VEGF. Blood 2005;105:4463-4469.
24. Schmandt SM, Packer RJ, Vezina LJ, et al. Spontaneous regression of low-grade astrocytomas in childhood. Pediatr Neurosurg 2000;32:132-136.
25. Kernan JC, Horgan MA, Piatt JH, et al. Spontaneous involution of a diencephalic astrocytoma. Pediatr Neurosurg 1998;29:149-153.
26. Asnaghi L, Bruno P, Pruilla M, et al. mTOR: a protein kinase switching between life and death. Pharmacol Res 2004;50:545-549.
27. Vignot S, Faivre S, Aguirre D, et al. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-537.
28. Goudar RK, Shi Q, Hjelmeland MD, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005;4:101-112.
29. Heimberger AB, Wang E, McGary EC, et al. Mechanisms of action of rapamycin in gliomas. Neuro-oncology 2005;7:1-11.
30. Galanis E, Buckner JC, Maurer MJ, et al. Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: North Central Cancer Treatment Group. J Clin Oncol 2005;23:5294-5304.
31. Huang S, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat 2001;4:378-391.
32. El-Hashemite N, Zhang H, Walker V, et al. Perturbed IFN-gamma-Jak-signal transducers and activators of transcription signaling in tuberous sclerosis mouse models: synergistic effects of rapamycin-IFN-gamma treatment. Cancer Res 2004;64:3436-3443.